ArticleThe journal of allergy and clinical immunology. Global2026
NSAID drug hypersensitivity in a United States-based population: An assessment of quality of life.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity reactions are common and can lead to medication avoidance and health anxiety. Objective: Despite their frequency, the specific impact of NSAID hypersensitivity on quality of life in a US population remains underexplored. We therefore aimed to explore this impact. Methods: We conducted a cross-sectional survey to evaluate drug-related quality of life using the validated Drug Hypersensitivity Quality of Life Questionnaire, a 15-item tool measuring the impact of drug allergy on quality of life. The study population consisted of adults with self-reported NSAID allergy from January 2014 to January 2024 at a tertiary academic medical center and a county hospital in Dallas, Texas. Results: In total, 154 adults had NSAID allergy documented in their electronic medical record. All 154 individuals were contacted, and of the 70 who were reached, 61 completed the survey (79% female, 61% White, 38% Black, and 28% Hispanic). The majority (87%) reported prior NSAID reactions, with common symptoms including dyspnea (52%) and rash (33%). Their mean Drug Hypersensitivity Quality of Life Questionnaire score was 42.87 plus or minus 15.52, indicating a substantial burden on quality of life. Top concerns included fear of receiving an allergy-provoking medication during an emergency situation and the desire for allergist input before medical use. Lifestyle limitations were reported as minimal. Comorbid aspirin-exacerbated respiratory disease and chronic spontaneous urticaria were reported in 34% and 20% of the participants, respectively. Conclusions: NSAID hypersensitivity is associated with significant quality of life burden in a US population, driven by anxiety around medication safety. The study findings support the need for comprehensive allergy evaluation and patient education, as well as a need for the consideration of delabeling strategies regarding drug-related quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.